C4 Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
CCCC$3.00-4.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows used in operating activities: | ||
| Net loss | $(84,508) | $(70,743) |
| Adjustments to reconcile net loss to cash used in operating activities: | ||
| Stock-based compensation expense | 15,092 | 21,427 |
| Loss on impairment of long-lived assets | 10,733 | — |
| Depreciation and amortization expense | 1,531 | 1,338 |
| Reduction in carrying amount of right-of-use asset | 5,005 | 4,790 |
| Net accretion of discounts on marketable securities | (1,879) | (4,315) |
| Other | 78 | 53 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (3,440) | 1,458 |
| Prepaid expenses and other current and long-term assets | 3,402 | (4,300) |
| Accounts payable | 4 | 57 |
| Accrued expenses and other current liabilities | (8,118) | (5,242) |
| Operating lease liability | (4,294) | (3,881) |
| Deferred revenue | (10,155) | 12,133 |
| Net cash used in operating activities | (76,549) | (47,225) |
| Cash flows provided by (used in) investing activities: | ||
| Proceeds from maturities of marketable securities | 166,731 | 178,781 |
| Purchases of marketable securities | (94,003) | (243,537) |
| Purchases of property and equipment, net | (596) | (184) |
| Net cash provided by (used in) investing activities | 72,132 | (64,940) |
| Cash flows provided by (used in) financing activities: | ||
| Proceeds from issuance of common stock pursuant to the at-the-market equity program, net | 7,526 | 24,370 |
| Proceeds from issuance of common stock pursuant to the Betta Pharma Stock Purchase Agreement | — | 20,000 |
| Proceeds from exercise of stock options | 107 | 667 |
| Payments for repurchase of common stock for tax withholding | (179) | (194) |
| Other | 273 | 381 |
| Net cash provided by financing activities | 7,727 | 45,224 |
| Net change in cash, cash equivalents and restricted cash | 3,310 | (66,941) |
| Cash, cash equivalents and restricted cash at beginning of period | 58,942 | 130,033 |
| Cash, cash equivalents and restricted cash at end of period | $62,252 | $63,092 |
| Reconciliation of cash, cash equivalents and restricted cash: | ||
| Cash, cash equivalents and restricted cash at end of period | $62,252 | $63,092 |
| Less: restricted cash | (3,443) | (3,443) |
| Cash and cash equivalents at end of the period | $58,809 | $59,649 |
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Supplemental disclosures of cash flow information: | ||
| Cash paid for leases | $6,812 | $6,614 |
| Supplemental disclosures of non-cash investing activities: | ||
| Capital expenditures in accounts payable and accrued expenses | $25 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.